Marinomed Biotech AG (MARI) Fair Value & Analysis
Healthcare · AT · Market cap €19.9M
Fair value as of: May 31, 2026
From 3 valuation models · updated 30 days ago
Share price −8.0% over the past month.
Price vs Fair Value (12 months)
12‑month range €9.90 – €22.84 · fair‑value band €4.45 – €7.42 · the €9.95 price screens above the €5.94 fair value. As of May 31, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Marinomed Biotech AG (MARI) currently trades at €9.95, while our model-based Fair Value estimate is €5.94 — implying the stock looks roughly 40.3% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at €8.0M. Revenue declined 76.9% year over year. Net debt stands at €26.5M. The stock trades on a trailing P/E of 1.8. Fundamentals as of May 31, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of May 31, 2026. TTM = trailing twelve months.
About the company
Marinomed Biotech AG operates as a biopharmaceutical company in Austria, other European countries, and internationally. Its lead products include Budesolv for the treatment of allergic rhinitis in late-stage clinical development; and Tacrosolv for the treatment of inflammatory eye diseases in Phase II clinical studies. The company also develops Satiasolv for pain immune reactions in the preclinical development phase. In addition, it provides Solv4U for formulation development and biopharmaceutical testing services. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Marinomed Biotech AG reported revenue of €4.7M in FY2024 versus €8.1M in FY2020, a compound −12.6%/yr. Reported net income was −€15.4M in FY2024.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of May 31, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN | $612.50 | $1,280 | +109% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Marinomed Biotech AG (MARI) undervalued?
What is the fair value of MARI?
What is the quality score of MARI?
What is the revenue of Marinomed Biotech AG (MARI)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.